|
|||||
|
|
| 新一代人工智能技术驱动下的新药研发 | |
| 引用本文： | 吴昊,林铭,孙懿,赵欣,蒲小平. 新一代人工智能技术驱动下的新药研发[J]. 中国药理学通报, 2019, 0(7): 889-893 |
| 作者姓名： | 吴昊 林铭 孙懿 赵欣 蒲小平 |
| 作者单位： | 1.北京大学药学院分子与细胞药理学系 |
| 基金项目： | “十三五”国家科技重大新药创制项目(No 2017ZX09101003-009-006);国家自然科学基金资助项目(No U1603128) |
| 摘 要： | 传统新药研发风险高而且周期长,资金投入也逐年增长,而人工智能(artificial intelligence,AI)技术可以改变传统新药研发模式,提高研发效率并降低再研成本。AI技术不仅能应用于靶点筛选,还能应用于表型筛选(phenotypic screening),从而开展针对复杂疾病的新药研发,同时,小样本学习使得AI技术更加具有普适性。而AlphaGo Zero的出现为AI技术带来重大突破,将会推动新药研发的快速发展。 |
| 关 键 词： | 新药研发 人工智能技术 靶点筛选 表型筛选 小样本学习 AlphaGo ZERO |
Research and development of new drugs driven by novel generation AI technology |
|
| WU Hao,LIN Ming,SUN Yi,ZHAO Xin,PU Xiao-ping. Research and development of new drugs driven by novel generation AI technology[J]. Chinese Pharmacological Bulletin, 2019, 0(7): 889-893 | |
| Authors: | WU Hao LIN Ming SUN Yi ZHAO Xin PU Xiao-ping |
| Affiliation: | (Dept of Molecular and Cellular Pharmacology, School of Pharmaceutical Science, Peking University, Beijing 100191,China) |
| Abstract: | Traditional new drug research and development is of high risk and long-term, with increasing investment year by year, which can be altered by AItechnology to improve the efficiency of R&D and decrease the cost of re-research. AI technology can be applied not only to target screening, but also to phenotypic screening to develop new drugs for complex diseases. At the same time, one-shot learning makes AI technology more comprehensive. The emergence of AlphaGo Zero has brought about a major breakthrough in AI technology, which will promote the rapid development of new drug R&D. |
| Keywords: | new drug research and development AI technology target screening phenotypic screening one-shot learning AlphaGo Zero |
| 本文献已被 维普 等数据库收录！ | |